Handa Pharmaceuticals, Inc. (TPEX:6620)
Taiwan · Delayed Price · Currency is TWD 124.00
+11.00 (9.73%)
Sep 8, 2026, 12:37 PM CST
Handa Pharmaceuticals Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,211 | 1,729 | 830.67 | 1,106 | 197.68 | 29.24 | |
Revenue Growth | -9.46% | 108.17% | -24.92% | 459.66% | 576.16% | 1.30% |
Cost of Revenue | 225.12 | 267.48 | 1.17 | 1.3 | 18.71 | 1.46 |
Gross Profit | 985.9 | 1,462 | 829.5 | 1,105 | 178.97 | 27.77 |
Selling, General & Admin | 155.17 | 165.02 | 119.54 | 144.25 | 87.31 | 72.67 |
Research & Development | 376.86 | 362.57 | 291.91 | 267.34 | 179.78 | 208.99 |
Operating Expenses | 532.03 | 527.59 | 411.44 | 411.59 | 267.09 | 281.66 |
Operating Income | 453.87 | 934.18 | 418.06 | 693.43 | -88.12 | -253.88 |
Interest Expense | -1.09 | -1.04 | -0.49 | -0.22 | -0.28 | -0.23 |
Interest & Investment Income | 79.67 | 59.21 | 57.06 | 18.16 | 0.5 | 0.29 |
Earnings From Equity Investments | -1.34 | 0.29 | -1.81 | 2.37 | - | - |
Currency Exchange Gain (Loss) | 71.29 | -37.8 | 26.9 | 1.71 | 44.02 | -7.27 |
Other Non Operating Income (Expenses) | -2.08 | -30.71 | -20.36 | 0.03 | 0.73 | 0.27 |
EBT Excluding Unusual Items | 600.33 | 924.14 | 479.36 | 715.47 | -43.15 | -260.82 |
Gain (Loss) on Sale of Assets | 12.84 | 12.84 | -0.19 | 4.61 | -0 | 0.02 |
Legal Settlements | - | - | - | 72.41 | - | - |
Pretax Income | 613.17 | 936.98 | 479.17 | 792.49 | -43.15 | -260.8 |
Income Tax Expense | 122.95 | 187.2 | 6.43 | 65.6 | -3.14 | -13.13 |
Net Income | 490.22 | 749.77 | 472.74 | 726.89 | -40.01 | -247.67 |
Net Income to Common | 490.22 | 749.77 | 472.74 | 726.89 | -40.01 | -247.67 |
Net Income Growth | -21.02% | 58.60% | -34.96% | - | - | - |
Shares Outstanding (Basic) | 161 | 154 | 140 | 134 | 126 | 118 |
Shares Outstanding (Diluted) | 162 | 155 | 141 | 135 | 126 | 118 |
Shares Change | 10.81% | 10.09% | 4.73% | 7.29% | 6.65% | 1.87% |
EPS (Basic) | 3.04 | 4.85 | 3.37 | 5.41 | -0.32 | -2.10 |
EPS (Diluted) | 3.02 | 4.83 | 3.35 | 5.40 | -0.32 | -2.10 |
EPS Growth | -28.71% | 44.18% | -37.96% | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 633.29 | 226.72 | 489.84 | 667.42 | -212.21 | -184.82 |
Free Cash Flow Per Share | 3.90 | 1.46 | 3.47 | 4.95 | -1.69 | -1.57 |
Dividend Per Share | 2.000 | 2.000 | 1.507 | 1.000 | - | - |
Dividend Growth | 32.73% | 32.73% | 50.68% | - | - | - |
Gross Margin | 81.41% | 84.53% | 99.86% | 99.88% | 90.53% | 95.00% |
Operating Margin | 37.48% | 54.02% | 50.33% | 62.68% | -44.58% | -868.42% |
Profit Margin | 40.48% | 43.36% | 56.91% | 65.70% | -20.24% | -847.17% |
Free Cash Flow Margin | 52.29% | 13.11% | 58.97% | 60.33% | -107.35% | -632.19% |
EBITDA | 604.86 | 1,085 | 421.12 | 698.48 | -81.3 | -245.05 |
EBITDA Margin | 49.95% | 62.77% | 50.70% | 63.14% | -41.13% | - |
D&A For EBITDA | 150.99 | 151.25 | 3.06 | 5.06 | 6.82 | 8.83 |
EBIT | 453.87 | 934.18 | 418.06 | 693.43 | -88.12 | -253.88 |
EBIT Margin | 37.48% | 54.02% | 50.33% | 62.68% | -44.58% | - |
Effective Tax Rate | 20.05% | 19.98% | 1.34% | 8.28% | - | - |